Last reviewed · How we verify
NCT06004349
Autoimmune and Autoinflammatory Genetics Study
trial in VEXAS Syndome in 1,500 participants. Currently enrolling.
5 April 2032
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 15 April 2022 |
| Primary completion | 5 April 2032 |
| Estimated completion | 5 April 2032 |
| Sites | 2 locations across United States |
Conditions studied
- VEXAS Syndome — all drugs for VEXAS Syndome →
- Autoinflammatory Disease — all drugs for Autoinflammatory Disease →
- Autoimmune Disease — all drugs for Autoimmune Disease →
- Rheumatic Disease — all drugs for Rheumatic Disease →
Sponsor
NYU Langone Health — full company profile →
Who can join
1 Month and older, any sex, with VEXAS Syndome or Autoinflammatory Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Shared and distinct mechanisms of UBA1 inactivation across different diseases.
Collins JC, Magaziner SJ, English M, Hassan B, et al · · 2024 · cited 37× · PMID 38360993 · DOI 10.1038/s44318-024-00046-z -
Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome.
Ospina Cardona D, Rodriguez-Pinto I, Iosim S, Bonet N, et al · · 2024 · cited 3× · PMID 38552317 · DOI 10.1093/rheumatology/keae201 -
Cell autonomous inflammation in VEXAS is mediated by cGAS-STING
· 2026
Verify or expand the search:
- PubMed search for NCT06004349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06004349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06004349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing